MX2019007350A - Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. - Google Patents

Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.

Info

Publication number
MX2019007350A
MX2019007350A MX2019007350A MX2019007350A MX2019007350A MX 2019007350 A MX2019007350 A MX 2019007350A MX 2019007350 A MX2019007350 A MX 2019007350A MX 2019007350 A MX2019007350 A MX 2019007350A MX 2019007350 A MX2019007350 A MX 2019007350A
Authority
MX
Mexico
Prior art keywords
treatment
bovine
compounds
respiratory disease
swine respiratory
Prior art date
Application number
MX2019007350A
Other languages
English (en)
Inventor
Berger Michael
Meyer Thorsten
Warrass Ralf
Ullrich Joachim
Linder Michael
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2019007350A publication Critical patent/MX2019007350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos para su uso en el tratamiento de enfermedades respiratorias de animales, especialmente enfermedad respiratoria bovina o porcina (BRD y SRD).
MX2019007350A 2016-12-23 2017-12-22 Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. MX2019007350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16206843 2016-12-23
PCT/EP2017/084364 WO2018115432A2 (en) 2016-12-23 2017-12-22 Compounds for the treatment of bovine or swine respiratory disease

Publications (1)

Publication Number Publication Date
MX2019007350A true MX2019007350A (es) 2019-11-05

Family

ID=57614227

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007350A MX2019007350A (es) 2016-12-23 2017-12-22 Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MX2022002056A MX2022002056A (es) 2016-12-23 2019-06-19 Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022002056A MX2022002056A (es) 2016-12-23 2019-06-19 Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.

Country Status (9)

Country Link
US (2) US11406617B2 (es)
EP (1) EP3558284A2 (es)
JP (2) JP7082445B2 (es)
CN (1) CN110300578B (es)
AR (1) AR110440A1 (es)
AU (1) AU2017383069B2 (es)
BR (1) BR112019012861A2 (es)
MX (2) MX2019007350A (es)
WO (1) WO2018115432A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019013016B1 (pt) * 2016-12-23 2023-05-02 Intervet International B.V. Compostos antibacterianos, composição farmacêutica que os compreende e uso dos referidos compostos
BR112020016270A2 (pt) * 2018-02-10 2020-12-15 Kbp Biosciences Co., Ltd. Composto atuando como antibióticos
US11419876B2 (en) 2019-09-06 2022-08-23 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
CN110563611B (zh) * 2019-09-19 2021-02-02 中国医学科学院医药生物技术研究所 一种异羟肟酸类衍生物及其制备方法和应用
CN111534613A (zh) * 2019-11-12 2020-08-14 广东美格基因科技有限公司 用于检测产毒肺炎支原体的荧光定量pcr方法及相应的试剂盒
WO2023118558A1 (en) 2021-12-24 2023-06-29 Intervet International B.V. Process of the preparation of hydroxylamine derivatives
AR128074A1 (es) 2021-12-24 2024-03-20 Intervet Int Bv Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074657A (en) 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
KR20040097187A (ko) 2002-03-21 2004-11-17 파마시아 앤드 업존 캄파니 동물의 귀로의 주사가능한 항생제의 투여 방법
US20040229955A1 (en) * 2003-01-08 2004-11-18 Andersen Niels H. Antibacterial agents
ES2602615T3 (es) 2007-06-12 2017-02-21 Achaogen, Inc. Agentes antibacterianos
DK2562155T3 (da) 2010-04-20 2019-06-24 Fujifilm Toyama Chemical Co Ltd Hydroxaminsyrederivat
WO2012031298A2 (en) * 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
EP2847162A1 (en) 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2014165075A1 (en) * 2013-03-12 2014-10-09 Achaogen, Inc. Antibacterial agents
BR112019013016B1 (pt) * 2016-12-23 2023-05-02 Intervet International B.V. Compostos antibacterianos, composição farmacêutica que os compreende e uso dos referidos compostos

Also Published As

Publication number Publication date
AR110440A1 (es) 2019-03-27
MX2022002056A (es) 2022-03-17
AU2017383069A1 (en) 2019-06-20
JP2022116149A (ja) 2022-08-09
RU2019122995A (ru) 2021-01-25
BR112019012861A2 (pt) 2019-12-10
WO2018115432A2 (en) 2018-06-28
CN110300578B (zh) 2022-12-13
WO2018115432A3 (en) 2019-02-07
US20230000813A1 (en) 2023-01-05
US20200085779A1 (en) 2020-03-19
JP7082445B2 (ja) 2022-06-08
JP7405903B2 (ja) 2023-12-26
JP2020502214A (ja) 2020-01-23
US11406617B2 (en) 2022-08-09
RU2019122995A3 (es) 2021-03-31
CN110300578A (zh) 2019-10-01
EP3558284A2 (en) 2019-10-30
AU2017383069B2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2019012233A (es) Anticuerpos anti-sirpa.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
BR112018069023A2 (pt) métodos de tratamento de doenças colestáticas
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2021015235A (es) Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
CL2019000846A1 (es) Proteína terapéutica.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EP4043012A4 (en) MEDICINAL PRODUCTS FOR TREATING ARTERY DISEASES AND USE THEREOF
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX2018007408A (es) Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.